Biomarker Discovery & Validation Services
Neurological disorders
ServiceActive
Key Facts
About NeuroDex
NeuroDex is a private, pre-revenue diagnostics company founded in 2019, specializing in biomarker development for neurological disorders through its neuron-derived exosome (NDE) technology. The company offers a suite of biomarker services and panels targeting key pathological proteins (e.g., α-Syn, TDP-43, Tau) to support pharmaceutical partners in clinical trials and translational research. With a team led by CEO/CSO Erez Eitan and operations in Boston, NeuroDex positions itself at the intersection of advanced diagnostics and the growing precision neurology market, though it faces risks typical of early-stage biotechs, including platform validation and funding needs.
View full company profileTherapeutic Areas
Other Neurological disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Biomarker Development Program | NeuroVision Imaging | Research |
| GlyT2 Inhibitor Program | Micar Innovation | Discovery |
| Clinical Trial Biomarker Support | NeuroDex | Service |
| CNS-Targeting Capsids | rAAVen Therapeutics | Pre-clinical |
| IVL-002 | InVirtuoLabs | Discovery |
| IVL-003 | InVirtuoLabs | Discovery |
| Neurology Diagnostics Program | Aptus Biosciences | Discovery |
| GM1 Ganglioside-based Therapies | TRB Chemedica International | Commercial / Development |
| Undisclosed Neurology Programs | BridGene Biosciences | Discovery |
| iPSC Platform Programs | Evotec | Preclinical Research |
| ExacTcell Platform | Tevogen Bio | Discovery/Preclinical |